Companies Dominating the Myositis Treatment Landscape
- Baxter International, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Novartis AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Pfizer Inc.
- Becton, Dickinson and Company
- IBSRELA
- Indegene
Browse Key Market Insights with Data Illustration:
In the News
-
IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
-
Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).
